Improvement of Trimetazidine on Viability of Bone Marrow Mesenchymal Stem Cells of In Vitro Hypoxia Model and In Vivo Myocardial Infarction Model in Rats

Objective:To investigate the improvement of trimetazidine(TMZ) on viability of bone marrow mesenchymal stem cells(MSCs) in an in vitro model of hypoxia culture and in vivo model of acute myocardial infarction(AMI) in rats. Methods:In vitro:Rats' MSCs were cultured in serum-free medium and exposed to hypoxia condition,and then examined at the third passage for their viability and apoptosis by transmission electron microscopy and flow cytometry.In vivo:AMI model was created by coronary artery ligation.30 Wista rats were randomly divided into 3 groups,n=10 in each group.AMI control group,the serum-free medium was injected;MSCs alone group,MSCs(4×107cells) were injected into the borderline of infarcted myocar-dium and MSCs+TMZ group,the rats were fed with TMZ 2.08mg/(kg·day) from 3 days before AMI to 28 days after AMI.Cardiac structure and function were assessed by echocardiography 28 days after MSCs implantation.The viability and apoptosis of implanted MSCs were detected at the borderline of infarcted myocardium. Results:In vitro:TMZ-treated MSCs presented half amount lower apoptosis rate than those without TMZ-treated MSCs under hypoxia culture.In vivo:Compared with AMI control group,the myocardial infarction sizes were significantly smaller in MSCs alone group and in MSCs+TMZ group,the cardiac function was significantly improved.Compared with MSCs alone group,MSCs had the higher viability and lower apoptosis,had the smaller size of infarction and the better cardiac function in MSCs + TMZ group. Conclusion:The combination of MSCs with TMZ implantation is superior to MSCs alone for higher MSCs viability and better cardiac function recovery in AMI model in rats.